Filters








1,180 Hits in 2.0 sec

J.-C. Marquet, (dir.) – L'Europe, déjà, à la fin des temps préhistoriques

Charles-Tanguy Le Roux
2007 Revue archéologique de l Ouest  
Charles-Tanguy Le Roux L'ouvrage s'ouvre sur un chapitre introductif (ch. 1 : Présentation générale des sites), à la suite duquel les différents sites archéologiques sont présentés les uns après les autres  ...  (ISBN 978-2-912610-11-9 ; 8 ).L'association en Région Centre pour l'Histoire et l'Archéologie a chargé Jean-Claude Marquet de réaliser, avec le soutien du programme Culture 2000 de l'Union européenne,  ... 
doi:10.4000/rao.482 fatcat:pmrfwxvrqzcezgpbhqjbydneam

Digital holography under non paraxial conditions

Simon Thibault, Charles Pichette, Michel Piché, Pierre Marquet, Jung-Young Son, Bahram Javidi, Osamu Matoba
2018 Three-Dimensional Imaging, Visualization, and Display 2018  
The knowledge of the exact complex (amplitude and phase) wavefield scattered for different illuminating beams allows the computation of the 3D spatial distribution of a specimen. This work looks on how diffraction tomography can behave under high numerical aperture focusing conditions. Scalar theory is no longer valid in such system and nonparaxial vectorial field theory must be used. 'Numerical methods such as FDTD techniques can also be used to investigate the interaction of this field with the specimen.
doi:10.1117/12.2307673 fatcat:fauu5rx2hvgmpeyzjbjrmxifea

Species dispersal and biodiversity in human-dominated metacommunities

David W. Shanafelt, Jean Clobert, Eli P. Fenichel, Michael E. Hochberg, Ann Kinzig, Michel Loreau, Pablo A. Marquet, Charles Perrings
2018 Journal of Theoretical Biology  
The concept of the Anthropocene is based on the idea that human impacts are now the primary drivers of changes in the earth's systems, including ecological systems. In many cases, the behavior that causes ecosystem change is itself triggered by ecological factors. Yet most ecological models still treat human impacts as given, and frequently as constant. This undermines our ability to understand the feedbacks between human behavior and ecosystem change. Focusing on the problem of species
more » ... l, we evaluate the effect of dispersal on biodiversity in a system subject to predation by humans. People are assumed to obtain benefits from (a) the direct consumption of species (provisioning services), (b) the non-consumptive use of species (cultural services), and (c) the buffering effects of the mix of species (regulating services). We find that the effects of dispersal on biodiversity depend jointly on the competitive interactions among species, and on human preferences over species and the services they provide. We find that while biodiversity may be greatest at intermediate levels of dispersal, this depends on structure of preferences across the metacommunity.
doi:10.1016/j.jtbi.2018.08.041 pmid:30176249 pmcid:PMC6161821 fatcat:zu5vejgzmbaivc36ymgqyihwe4

A compilation flow for parametric dataflow

Mickaël Dardaillon, Kevin Marquet, Tanguy Risset, Jérôme Martin, Henri-Pierre Charles
2014 Proceedings of the 2014 International Conference on Compilers, Architecture and Synthesis for Embedded Systems - CASES '14  
Efficient programming of signal processing applications on embedded systems is a complex problem. High level models such as Synchronous dataflow (SDF) have been privileged candidates for dealing with this complexity. These models permit to express inherent application parallelism, as well as analysis for both verification and optimization. Parametric dataflow models aim at providing sufficient dynamicity to model new applications, while at the same time maintaining the high level of
more » ... y needed for efficient real life implementations. This paper presents a new compilation flow that targets parametric dataflows. Built on the LLVM compiler infrastructure, it offers an actor based C++ programming model to describe parametric graphs, a compilation front-end providing graph analysis features, and a retargetable back-end to map the application on real hardware. This paper gives an overview of this flow, with a specific focus on scheduling. The crucial gap between dataflow models and real hardware on which actor firing is not atomic, as well as the consequences on FIFOs sizing and execution pipelining are taken into account.The experimental results illustrate our compilation flow applied to compilation of 3GPP LTE-Advanced demodulation on a heterogeneous MPSoC with distributed scheduling features. This achieves performances similar to time-consuming hand made optimizations.
doi:10.1145/2656106.2656110 dblp:conf/cases/DardaillonMRMC14 fatcat:2mgcsosqlzejpdtvwyru5jasbm

A New Compilation Flow for Software-Defined Radio Applications on Heterogeneous MPSoCs

Mickaël Dardaillon, Kevin Marquet, Tanguy Risset, Jérôme Martin, Henri-Pierre Charles
2016 ACM Transactions on Architecture and Code Optimization (TACO)  
It is derived from PinaVM [Marquet and Moy 2010], a front end for SystemC analysis.  ...  Using slicing [Marquet and Moy 2010], we execute only the instructions required for the computation of this address.  ... 
doi:10.1145/2910583 fatcat:zvgvyrsahrbjlkretgonnbnbk4

Prostaglandin D2 amplifies lupus disease through basophil accumulation in lymphoid organs

Christophe Pellefigues, Barbara Dema, Yasmine Lamri, Fanny Saidoune, Nathalie Chavarot, Charlotte Lohéac, Emeline Pacreau, Michael Dussiot, Caroline Bidault, Florian Marquet, Mathieu Jablonski, Jonathan M. Chemouny (+9 others)
2018 Nature Communications  
C57BL/6J WT mice were purchased from Charles River Laboratories (L'Arbresle, France).  ... 
doi:10.1038/s41467-018-03129-8 pmid:29463843 pmcid:PMC5820278 fatcat:shuklfr3cnfwzl4h6phqcrhbqu

Approaching a state shift in Earth's biosphere

Anthony D. Barnosky, Elizabeth A. Hadly, Jordi Bascompte, Eric L. Berlow, James H. Brown, Mikael Fortelius, Wayne M. Getz, John Harte, Alan Hastings, Pablo A. Marquet, Neo D. Martinez, Arne Mooers (+10 others)
2012 Nature  
Localized ecological systems are known to shift abruptly and irreversibly from one state to another when they are forced across critical thresholds. Here we review evidence that the global ecosystem as a whole can react in the same way and is approaching a planetary-scale critical transition as a result of human influence. The plausibility of a planetary-scale 'tipping point' highlights the need to improve biological forecasting by detecting early warning signs of critical transitions on global
more » ... as well as local scales, and by detecting feedbacks that promote such transitions. It is also necessary to address root causes of how humans are forcing biological changes.
doi:10.1038/nature11018 pmid:22678279 fatcat:5njlcgmbynefxh7d257frfro4i

A Detailed Power System Planning Model: Estimating the Long-Run Impact of Carbon-Reducing Policies

Daniel Shawhan, John Taber, Ray Zimmerman, Jubo Yan, Charles Marquet, William Schulze, Richard Schuler, Robert Thomas, Daniel Tylavsky, Di Shi, Nan Li, Ward Jewell (+2 others)
2015 2015 48th Hawaii International Conference on System Sciences  
In this paper, a much more detailed representation of the nation's electricity system than has been traditionally used in policy models is employed. This detailed representation greatly increases the computational difficulty of obtaining optimal solutions, but is necessary to accurately model the location of new investment in generation. Given the proposed regulation of CO 2 emissions from US power plants, an examination of economically efficient policies for reducing these emissions is
more » ... d. The model incorporates realistic physical constraints, investment and retirement of generation, and price-responsive load to simulate the effects of policies for limiting CO 2 emissions over a twenty-year forecast horizon. Using network reductions for each of the three electric system regions in the U.S. and Canada, an optimal economic dispatch, that satisfies reliability criteria, is assigned for 12 typical hour-types in each year. Three scenarios are modeled that consider subsidies for renewables and either CO 2 emissions regulation on new investment or cap-and-trade. High and low gas price trends are also simulated and have large effects on prices of electricity but small impacts on CO 2 emissions. Low gas prices with cap-and-trade reduce CO 2 emissions the most; large subsidies for renewables alone do not reduce carbon emissions much below existing levels. Extensive retirement of coal-fired power plants occurs in all cases.
doi:10.1109/hicss.2015.300 dblp:conf/hicss/ShawhanTZYMSSTT15 fatcat:5p6nvp2kqrggdgnd3oxcwlurci

How to Improve Clinical Research Performances in France?

Vincent Diebolt, Yannick Pletan, François Ballet, Jehan Michel Behier, Pierre Bey, Antoine Cournot, Hervé Decousus, Jean Deregnaucourt, Élisabeth Devilliers, Claude Dubray, Claude Gaultier, François Gueyffier (+16 others)
2008 The´rapie (Paris)  
The general objective of this study was to proceed an inventory of measures which could help to improve the efficiency of clinical research in France. Method. Thanks to the discussion between the members of the round-table conference (composed of medical doctors (MD)/investigators; hospital managers; representatives of industrial promoters; general practitioners...), we have looked over the difficulties that meets clinical research in France nowadays. Results. We identified four fields of
more » ... : 1) availibility of resources for carrying out the trials in time and in quality; 2) feasability of the clinical trials, in their design and for the recruitment which depends on both of the investigation centers and patients (what is the image of human testing in the society?); 3) skills and motivation of all the elements of staffs in charge of clinical trials (MD; nurses; and the new jobs in medical research); 4) promptness and efficiency of the administrative organisation for a fast starting up of the trials. Conclusion. This study, which doesn't pretend to sufficiency, shows the gap of improvement for French clinical trials organisation.
doi:10.2515/therapie:2008046 pmid:18937908 fatcat:2nuhyhewobfxno4pqptqpnfmkm

Comment faire évoluer le paradigme du développement clinique et son découpage en phases I, II, III

Marion Bamberger, Nicholas Moore, Philippe Lechat, Michel Azizi, Patrick Blin, Myriam Bouhassira, Dominic Cellier, Jean-Paul Demarez, Xavier Duval, François Gueyffier, Claire Le Jeunne, Christian Libersa (+13 others)
2011 The´rapie (Paris)  
Partant de la constatation que depuis 30 ans, le coût du développement augmente régulièrement à mesure que le nombre de nouvelles entités chimiques atteignant le marché décroît, comment faire des « économies » en termes de développement clinique, l'objectif étant un accès plus rapide au médicament, pour les besoins médicaux non couverts ? Plusieurs instruments existent pour permettre une mise à disposition plus rapide de produits innovants : les autorisations temporaires d'utilisation ou ATU
more » ... i ne sont pas concernées par ce travail), les autorisations de mise sur le marché (AMM) conditionnelles, les AMM sous circonstances exceptionnelles. Ces éléments sont repris dans la « road map » de l'Agence européenne du médicament, (European Medicines Agency ou EMA), qui dit : « A key issue for Regulators will be if a more "staggered" approval should be envisaged, characterised by a better defined/more restricted population of good responders, followed by a broadening of the population postauthorisation when more "real life" data are available. In addition, maximising the value of information generated in the post-authorisation phase should be developed through the use of cohorts and other prospectively collected use data, especially in the case of conditional marketing authorisations. » Le règlement intérieur de la Commission de transparence pour sa part prévoit la notion d'examen préliminaire : afin de préparer au mieux l'instruction des dossiers des produits présumés innovants et de limiter les délais, le bureau peut engager une étude préliminaire dès le dépôt du dossier au Comité des spécialités pharmaceutiques humaines (CHMP). Il peut à cette occasion solliciter de la firme des éléments d'information et faire appel à des experts externes. La mise en oeuvre de cette étude préliminaire n'exonère pas la firme de l'obligation de déposer un dossier complet. Les études post inscription demandées par la commission de transparence (ISPEP) le sont souvent dans le cas d'hésitations sur le niveau d'amélioration du service médical rendu ou ASMR (niveau II/III ou IV/V). Ces demandes concernent essentiellement des incertitudes sur la transposabilité, le profil patient ou le respect du bon usage. Parmi les études dont les résultats ont été rendus, dans 15 cas les résultats sont en conformité avec les attentes, dans 6 cas elles ont abouti à des réévaluations à la baisse, enfin dans 3 cas elles étaient non conclusives. Les recommandations finales de la Table Ronde étaient :
doi:10.2515/therapie/2011043 pmid:27392459 fatcat:4p2psijfezhbrhwaagorg2qdli

How to Improve the Clinical Development Paradigm and its Division into Phases I, II and III

Marion Bamberger, Nicholas Moore, Philippe Lechat, Michel Azizi, Patrick Blin, Myriam Bouhassira, Dominic Cellier, Jean-Paul Demarez, Xavier Duval, François Gueyffier, Claire Le Jeunne, Christian Libersa (+13 others)
2011 The´rapie (Paris)  
Based on the observation that over the last 30 years the cost of development has risen regularly as the number of new chemical entities reaching the market has fallen, how can "savings" be made in terms of clinical development, the objective being more rapid access to a drug for medical needs that are not covered? Several instruments exist to enable innovative products to be made available more quickly: temporary use authorisations, which are not concerned by this work (ATUs), conditional
more » ... ing authorisations (MAs) and MAs under exceptional circumstances. These aspects have been taken up in the European medicines agency (EMA)'s "Road Map", which states "A key issue for Regulators will be if a more "staggered" approval should be envisaged, characterised by a better defined/more restricted population of good responders, followed by a broadening of the population post-authorisation when more "real life" data are available. In addition, maximising the value of information generated in the post-authorisation phase should be developed through the use of cohorts and other prospectively collected use data, especially in the case of conditional marketing authorisations." The rules of procedure of the Transparency Commission for their part provide for the notion of preliminary examination: in order to prepare as best as possible the examination of dossiers of products assumed to be innovative and to limit delays, the office can undertake a preliminary study as soon as the dossier has been filed at the Committee for medicinal products for human use (CHMP). It may, at this time, request the firm to provide further information and may call on external experts. The implementation of this preliminary study does not exonerate the firm of the obligation of filing a complete dossier. The post inscription studies requested by the Transparency Commission (ISPEP -public health benefit and post-marketing studies) are usually requested in the case of hesitations regarding the level of improvement of the medical benefit (ASMR) [level II/III or IV/V]. Such requests mainly concern uncertainties regarding the transposability, the patient profile or correct usage in real life. Among the studies whose results were provided, in 15 cases the results were in line with expectations, in 6 cases they resulted in downward re-evaluations and the final 3 cases were inconclusive. The final recommendations of the round table were: c 2011 Société Française de Pharmacologie et de Thérapeutique Thérapie 2011 Juillet-août; 66 (4)
doi:10.2515/therapie/2011046 pmid:21851796 fatcat:dbsojrlvgbbgjk5c2f3wr2zlva

Comment améliorer les performances de la recherche clinique en France ?

Vincent Diebolt, Yannick Pletan, François Ballet, Jehan Michel Behier, Pierre Bey, Antoine Cournot, Hervé Decousus, Jean Deregnaucourt, Élisabeth Devilliers, Claude Dubray, Claude Gaultier, François Gueyffier (+16 others)
2008 The´rapie (Paris)  
Texte reçu le 15 juillet 2008 ; accepté le 30 juillet 2008 Mots clés : recherche clinique ; faisabilité ; qualification ; efficacité Résumé -L'objectif général de l'étude était d'identifier les mesures devant permettre d'améliorer la performance de la recherche clinique en France. Méthode. Grâce à la discussion entre les membres de la table-ronde (composée de médecins investigateurs ; responsables hospitaliers ; représentants de promoteurs industriels ; médecins généralistes...), nous avons
more » ... é en revue les difficultés que rencontrent la recherche clinique française aujourd'hui. Résultats. Nous avons identifié quatre champs d'action : 1) la disponibilité des ressources nécessaires à la conduite des protocoles de recherche (disponibilité en quantité et en temps, dans les délais les plus brefs) ; 2) la faisabilité, celle de l'essai dans le design de son protocole, celle du recrutement qui dépend à la fois du centre/équipe/réseau investigateur et des patients et de l'image qu'ils ont de l'expérimentation biomédicale ; 3) la qualification et la motivation des individualités et des métiers associés qui composent l'équipe conduisant les protocoles de recherche ; 4) la fluidité et l'efficacité de l'organisation administrative pour des temps préparatoires au démarrage des essais les plus réduits au profit du temps de réalisation de l'essai. Conclusion. Cette étude, qui n'a pas la prétention à l'exhaustivité, a montré l'ampleur des efforts pour améliorer l'organisation française d'essais cliniques.
doi:10.2515/therapie:2008045 pmid:27392546 fatcat:2brja2ldkfhkjci5gd5pzd6gae

Page 64 of Das Kunstwerk Vol. 1, Issue 10-11 [page]

1946 Das Kunstwerk  
Charles-Louis Philippe, der Verfasser wehmütiger und un- züchtiger Bücher, erklärte einmal über seinen Freund Mar- quet: „Er besigt einen Sinn für das Gleichgewicht und die Schwere der Dinge, die ihn vor  ...  ALBERT MARQUET Nach Bonnard starb in diesem Jahre ein zweiter franzö- sischer Maler von Bedeutung: Albert Marquet, Marquet schloß am 14. Juli 72jährig die Augen.  ... 

Rare Pathogenic Variants in Mitochondrial and Inflammation-Associated Genes May Lead to Inflammatory Cardiomyopathy in Chagas Disease

Maryem Ouarhache, Sandrine Marquet, Amanda Farage Frade, Ariela Mota Ferreira, Barbara Ianni, Rafael Ribeiro Almeida, Joao Paulo Silva Nunes, Ludmila Rodrigues Pinto Ferreira, Vagner Oliveira-Carvalho Rigaud, Darlan Cândido, Charles Mady, Ricardo Costa Fernandes Zaniratto (+18 others)
2021 Journal of Clinical Immunology  
Cardiomyopathies are an important cause of heart failure and sudden cardiac death. Little is known about the role of rare genetic variants in inflammatory cardiomyopathy. Chronic Chagas disease cardiomyopathy (CCC) is an inflammatory cardiomyopathy prevalent in Latin America, developing in 30% of the 6 million patients chronically infected by the protozoan Trypanosoma cruzi, while 60% remain free of heart disease (asymptomatic (ASY)). The cytokine interferon-γ and mitochondrial dysfunction are
more » ... nown to play a major pathogenetic role. Chagas disease provides a unique model to probe for genetic variants involved in inflammatory cardiomyopathy.
doi:10.1007/s10875-021-01000-y pmid:33660144 pmcid:PMC8249271 fatcat:qx4kuizbojaunhtvmnqom6gwum

Page 161 of La Revue de Paris Vol. 58, Issue 10 [page]

1951 La Revue de Paris  
Charles-Louis Philippe, Georges Besson, Léon Werth, Francis Jourdain avaient tracé déjà du « peintre de Paris » de forts beaux por- 1. Marquet (Éditions R. Laffont).  ...  . — Albert Marquet souriait, mais ne parlait pas.  ... 
« Previous Showing results 1 — 15 out of 1,180 results